New hope for hard-to-treat breast cancer: combo therapy enters human trials
NCT ID NCT07336771
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new two-drug combination (JSKN016 plus D-0502) in 60 people with advanced hormone receptor-positive, HER2-negative breast cancer whose disease worsened after standard hormone therapy. The goal is to see if the combination is safe and shrinks tumors. Participants receive the drugs either every 2 or 3 weeks by IV plus a daily pill.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer center
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••